Immune cell therapy for advanced non-small cell lung cancer
Part of Cancer, Lungs & breathing clinical trials.
This trial tests a new cell therapy called BST08, made from your own immune cells, for advanced non-small cell lung cancer that has not responded to at least two standard treatments. The goal is to see if this therapy is safe and can help shrink tumors.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be between 18 and 70 years old.
- You must have advanced non-small cell lung cancer (NSCLC) that does not have certain gene changes (driver mutations).
- You must have already tried at least two standard treatments, including an immunotherapy drug (like Keytruda, Opdivo, or Tecentriq), and the cancer still grew.
- You need to be in fairly good health and able to do most daily activities on your own.
- You must be able to have two small tumor samples taken for this trial.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a personalized treatment using your own immune cells (called TILs) to fight advanced non-small cell lung cancer that has progressed after standard therapy. You would have surgery to collect a tumor sample, then receive your expanded immune cells back as an infusion.
This trial tests an experimental immunotherapy called BNT116, given alone or with other drugs, for people with advanced non-small cell lung cancer (NSCLC). The goal is to see if it is safe and if it can help shrink tumors.
This trial tests two drugs, benmelstobart (immunotherapy) and anlotinib (a targeted therapy), alone or combined, before surgery for non-small cell lung cancer. The goal is to see if these drugs shrink the tumor enough to improve the chances of a complete response after surgery.
This trial tests a new combination of an investigational drug (SPGL008) with another therapy (SSGJ-706), with or without chemotherapy, for people with advanced non-small cell lung cancer that has not spread beyond the lungs or has spread to nearby areas. The goal is to see if this combination can help control the cancer.
This trial tests an experimental cell therapy (GC101) for people with advanced non-small cell lung cancer. It uses your own tumor-fighting immune cells, called TILs, grown in a lab and given back to you. The goal is to see if it can shrink tumors or slow the disease.
This trial tests a new treatment that combines a drug called SYS6010 with an immunotherapy (Enlonstobart) compared to the usual immunotherapy plus chemo for advanced lung cancer. The goal is to see if this combo works better and helps people with PD-L1 positive lung cancer live longer and feel better.
Hear when a new Non Small Cell Lung Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.